Lilly's Arxxant gets Priority Review

FDA accepted for filing and granted Priority Review to an NDA from Eli Lilly (LLY) for Arxxant ruboxistaurin ( LY333531) to treat diabetic retinopathy. The company would not disclose the PDUFA date fo...